Loading...
XIDX
INAF
Market cap23mUSD
Jul 01, Last price  
126.00IDR
Name

Indofarma Tbk PT

Chart & Performance

D1W1MN
XIDX:INAF chart
P/E
—
P/S
1.86
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-31.14%
Revenues
210.38b
-59.82%
684,039,648,7051,026,675,533,9391,273,162,479,1641,478,585,255,3951,125,055,390,9361,047,918,156,4701,203,466,970,6521,156,050,256,7201,337,498,191,7101,381,436,578,1151,621,898,667,6571,674,702,722,3281,631,317,499,0961,592,979,941,2581,359,175,249,6551,715,587,654,3992,901,986,532,8791,144,108,230,742523,599,087,434210,379,674,000
Net income
-334.49b
L-53.61%
9,594,742,64915,240,675,13811,076,807,0485,031,898,6802,125,637,96712,546,644,38836,919,316,55142,384,956,906-54,222,344,1421,166,073,4876,566,935,986-17,366,640,817-46,282,940,175-32,735,901,4287,960,962,72427,580,910-37,571,241,226-428,487,671,595-720,993,176,197-334,488,575,000
CFO
-21.65b
L-88.61%
-54,871,009,45773,151,865,24383,418,335,788-187,307,305,04840,557,994,67723,713,155,86929,396,516,728-40,914,557,262-141,616,973,090148,726,901,608134,284,985,660-317,962,543,661147,184,447,849-70,390,895,93120,790,922,34746,547,903,55392,899,478,946-409,853,009,714-190,104,481,175-21,653,684,335
Dividend
May 03, 20131.37 IDR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

PT Indofarma Tbk, together with its subsidiaries, manufactures and markets pharmaceutical products in Indonesia. The company trades in and distributes drugs, medical devices, medical supplies, extracts, and herbals; and operates laboratory. It also provides COVID-19 test services, including rapid diagnostic test antigen; reverse transcription polymerase chain reaction, and genose. The company also exports its products. The company was formerly known as PT Indofarma (Persero) Tbk. PT Indofarma Tbk was founded in 1918 and is headquartered in Bekasi, Indonesia. PT Indofarma Tbk operates as a subsidiary of PT. Bio Farma.
URL
https://indofarma.id/en/
IPO date
Apr 17, 2001
Employees
Domiciled in
ID
Incorporated in
ID

Valuation

Title
IDR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT